NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Was LL speaking on the P3 DCVAX trial yesterday with the "5 years without recurrence" remark?

P3 DCVax-L clinical trial.

Combo trials at UCLA

DC vaccine + poly-ICLC

-CyTOF identifies peripheral immune cell populations altered after treatment.
- Peripheral blood reveals robust interferon pathway activation following DC
vaccination + TLR agonists.
- Peripheral blood reveals robust interferon-induced response in patients
treated with DC vaccination + poly-ICLC
- Interferon signature in peripheral blood as a biomarker of response to
immunotherapy.
-Tumor-infiltrating lymphocyte content is predictive biomarker of survival after
DC vaccination

Adult Recurrent GBM Study

Phase 2 Clinical Trial of DC vaccine + poly-ICLC + PD-1 mAb

Preliminary survival analysis of DC vaccine + PD-1 mAb vs. adjuvant PD-1 mAb only cohort
Survival proportions: Survival of Survival: Two groups
1 = ATL-DC + PD1 Arm
2 = PD1 mAb only (adjuvant)Arm note: from the Neoadjuvant/ Adjuvant anti -PD-1 Study
Note: ATL-DC + PD1 arm did much better
Interim Survival Analysis of recGBM patients
Neoadj PD1 mAb + adj ATL-DC med OS = 275 days
Adj ATL-DC + PD -1 mAb med OS = not reached
Note: Adj ATL-DC + PD -1 mAb arm is doing much better vs. Neoadj PD1 mAb + adj ATL-DC